GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Quality Rank

Frontage Holdings (HKSE:01521) Quality Rank


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Frontage Holdings Quality Rank Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings (HKSE:01521) Business Description

Traded in Other Exchanges
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.